MRDD Archive

  • It’s “well known” that we all need to find the stronger inhibitors against any specific therapeutic target as possible. The motivation is that the strongest inhibitors are most probably less...

    Do we need those nM-inhibitors?

    It’s “well known” that we all need to find the stronger inhibitors against any specific therapeutic target as possible. The motivation is that the strongest inhibitors are most probably less...

    Continue Reading...

  • Prediction of toxic properties of small drug like molecules is a big challenge both from theoretical and practical points of view. Quantitatively people use different measures of toxicity such as...

    LD50 vs. MRDD: what’s death for a mice is good enough for a man

    Prediction of toxic properties of small drug like molecules is a big challenge both from theoretical and practical points of view. Quantitatively people use different measures of toxicity such as...

    Continue Reading...

  • Druglikeness is a qualitative concept used in drug design for an estimate on how “druglike” a prospective compound is. Usually it is estimated from the molecular structure, often even before...

    Drug likeness: what do bioavailability and toxicity properties tell us about druglikeness?

    Druglikeness is a qualitative concept used in drug design for an estimate on how “druglike” a prospective compound is. Usually it is estimated from the molecular structure, often even before...

    Continue Reading...

Get Adobe Flash playerPlugin by wpburn.com wordpress themes